Cytomegalovirus quantification: Where to next in optimising patient management?

被引:28
作者
Atkinson, Claire [1 ]
Emery, Vincent C. [1 ]
机构
[1] UCL London, Dept Infect, Ctr Virol, London, England
关键词
Antiviral therapy; HCMV disease; Pathogenesis; PCR; ORGAN-TRANSPLANT RECIPIENTS; POLYMERASE-CHAIN-REACTION; REAL-TIME PCR; VIRAL-LOAD; PREEMPTIVE THERAPY; CMV DISEASE; RENAL-TRANSPLANTATION; LIVER-TRANSPLANTATION; PP65; ANTIGENEMIA; IMMUNOCOMPROMISED PATIENTS;
D O I
10.1016/j.jcv.2011.04.007
中图分类号
Q93 [微生物学];
学科分类号
071005 [微生物学];
摘要
Background: Over the years quantification of cytomegalovirus (HCMV) load in blood has become a mainstay of clinical management helping direct deployment of antiviral therapy, assess response to therapy and highlight cases of drug resistance. Aims: The review focuses on a brief historical perspective of HCMV quantification and the ways in which viral load is being used to improve patient management. Methods: A review of the published literature and also personal experience at the Royal Free Hospital. Results: Quantification of HCMV is essential for efficient patient management. The ability to use real time quantitative PCR to drive pre-emptive therapy has improved patient management after transplantation although the threshold viral loads for deployment differ between laboratories. The field would benefit from access to a universal standard for quantification. Conclusions: We see that HCMV quantification will continue to be central to delivering individualised patient management and facilitating multicentre trials of new antiviral agents and vaccines in a variety of clinical settings. (c) 2011 Elsevier B. V. All rights reserved.
引用
收藏
页码:219 / 224
页数:6
相关论文
共 65 条
[1]
Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir [J].
Amir, Jacob ;
Wolf, Dana G. ;
Levy, Itzhak .
EUROPEAN JOURNAL OF PEDIATRICS, 2010, 169 (09) :1061-1067
[2]
[Anonymous], TRENDS TRANSPLANT
[3]
Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients [J].
Asberg, A. ;
Humar, A. ;
Rollag, H. ;
Jardine, A. G. ;
Mouas, H. ;
Pescovitz, M. D. ;
Sgarabotto, D. ;
Tuncer, M. ;
Noronha, I. L. ;
Hartmann, A. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (09) :2106-2113
[4]
Long-Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients [J].
Asberg, A. ;
Humar, A. ;
Jardine, A. G. ;
Rollag, H. ;
Pescovitz, M. D. ;
Mouas, H. ;
Bignamini, A. ;
Toez, H. ;
Dittmer, I. ;
Montejo, M. ;
Hartmann, A. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (05) :1205-1213
[5]
Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease [J].
Bowen, EF ;
Sabin, CA ;
Wilson, P ;
Griffiths, PD ;
Davey, CC ;
Johnson, MA ;
Emery, VC .
AIDS, 1997, 11 (07) :889-893
[6]
Human cytomegalovirus (HCMV) replication kinetics in stem cell transplant recipients following anti-HCMV therapy [J].
Buyck, Hubertus C. E. ;
Griffiths, Paul D. ;
Emery, Vincent C. .
JOURNAL OF CLINICAL VIROLOGY, 2010, 49 (01) :32-36
[7]
Comparison of molecular tests for detection and quantification of cell-associated cytomegalovirus DNA [J].
Caliendo, AM ;
Yen-Lieberman, B ;
Baptista, J ;
Andersen, J ;
Crumpacker, C ;
Schuurman, R ;
Spector, SA ;
Bremer, J ;
Lurain, NS .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (08) :3509-3513
[8]
A Commutable Cytomegalovirus Calibrator Is Required to Improve the Agreement of Viral Load Values between Laboratories [J].
Caliendo, Angela M. ;
Shahbazian, Mona D. ;
Schaper, Carl ;
Ingersoll, Jessica ;
Abdul-Ali, Deborah ;
Boonyaratanakornkit, Jerry ;
Pang, Xiao-Li ;
Fox, Julie ;
Preiksaitis, Jutta ;
Schoenbrunner, E. Ralf .
CLINICAL CHEMISTRY, 2009, 55 (09) :1701-1710
[9]
NUCLEIC-ACID SEQUENCE-BASED AMPLIFICATION [J].
COMPTON, J .
NATURE, 1991, 350 (6313) :91-92
[10]
Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation [J].
Cope, AV ;
Sabin, C ;
Burroughs, A ;
Rolles, K ;
Griffiths, PD ;
Emery, VC .
JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (06) :1484-1490